Evidence map›Paper›PMID 40560396›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Mapping breast cancer research on monoclonal antibodies: a data-driven approach using VOSviewer, Bibliometrix, and CiteSpace.

Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Manal Mohamed Elhassan Taha, Khaled A Sahli, Hatem Ahmed Salem Alqhtani, Moath Mohamed Farasani, Marwa Qadri, Abdulaziz Alarifi, Amani Khardali, Khulud Hamoud Alsaadi and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Siddig Ibrahim AbdelwahabHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia. siddigroa@yahoo.com.
Sivakumar S MoniHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Manal Mohamed Elhassan TahaHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Khaled A SahliGeneral Directorate of Medical Services, Ministry of Interior, Riyadh, Saudi Arabia.
Hatem Ahmed Salem AlqhtaniKing Fahad Central Hospital, Jazan, Saudi Arabia.
Moath Mohamed FarasaniPrince Mohamed Bin Naser Hospital Jazan, Jazan, Kingdom of Saudi Arabia.
Marwa QadriHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Abdulaziz AlarifiDepartment of Basic Sciences, College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Amani KhardaliDepartment of Clinical Pharmacy, College of Pharmacy, Jazan University, 45142, Jazan, Saudi Arabia.
Khulud Hamoud AlsaadiDepartment of Biological Sciences, Jeddah University, Jeddah, Saudi Arabia.
Abdullah FarasaniHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Nizar A KhamjanDepartment of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Humaid Al-ShamsiBurjeel Cancer Institute, P.O. Box 92510, Abu Dhabi, United Arab Emirates.
Jobran M MoshiHealth Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Saeed AlshahraniDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, 45142, Jazan, Saudi Arabia.
Ahmed SalawiDepartment of Pharmaceutics, College of Pharmacy, Jazan University, 45142, Jazan, Saudi Arabia.
Ahmad AssiriDepartment of Dermatology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Ayah IbrahimMinistry of Education, Jazan University, 45142, Jazan, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal Antibodies and Breast Cancer Research (MABCR) has progressed substantially, particularly in the areas of HER2-positive and triple-negative breast cancer. However, a comprehensive synthesis of global trends, influential contributors, and emerging research areas remains lacking. This study presents a bibliometric analysis of MABCR, highlighting major research trajectories, key publications, and evolving themes. Using data from the Scopus database spanning 1972 to 2024 and applying a multistep search strategy cross-validated with MeSH terms, 14,764 English-language original research articles were identified across 2125 sources. Non-research documents, duplicates, and retractions were excluded. Quantitative analysis was conducted using Bibliometrix, VOSviewer, and CiteSpace. The annual publication growth rate was 17.8%. The USA and China were the leading contributors, while Breast Cancer Research and Treatment emerged as the most prolific journal. Influential authors such as Slamon, Baselga, and Hortobagyi were identified based on publication volume, H-index, and citation impact. Co-citation analysis revealed major thematic clusters including HER2-positive and triple-negative breast cancer, trastuzumab deruxtecan, and the integration of machine learning in MABCR. Emerging areas of interest include HER2-low subtypes and tumor microenvironment profiling using radiomics and multi-omic approaches. This analysis provides a structured overview of MABCR, offering valuable insights to guide future research and foster innovation in precision oncology.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomedical ResearchBreast NeoplasmsBibliometricsErb-b2 Receptor Tyrosine KinasesFemaleHumansAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesBibliometric analysisBreast cancerMonoclonal antibodiesResearch trendsTargeted therapy

Identifiers

PMID40560396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.